L-Isoleucine

We are L-Isoleucine CAS:73-32-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


L-Isoleucine
 
An essential amino acid in human. Known as BCAAs (branched chained amino acids) which are the main components of muscle protein. It is widely used as an ingredient in infusion and infant formula.

Cas.No 73-32-5
Assay 99.0-101.0%
Specification White crystals or crystalline powder, odorless or slightly characteristic odor, slightly bitter taste
Applications Infusion, Cell culture media, Dietary Supplement
Packaging 25kg&50kg
Pharmacopeia JP,USP,EP,FCC
STORAGE Controlled room temperature in tight container

 
SPECIFICATION AND PROCEDURE

State of solution
(Transmittance)
Not Less Than 98.0%
pH 5.5~6.5
Specific rotation[α]20D +39.5~+41.5°
Specific rotation[α]25D +38.9~+41.8°
Ammonium (NH4) Not More Than 0.020%
Chloride (Cl) Not More Than 0.020%
Sulfate (SO4) Not More Than 0.020%
Iron (Fe) Not More Than 10 ppm
Heavy metals (Pb)** Not More Than 10 ppm
Arsenic (As2O3) Not More Than 1 ppm
Loss on drying Not More Than 0.20%
Residue on ignition Not More Than 0.10%
Related substances Not More Than 0.5%
Endotoxin* Less Than 6.0 EU/g
Assay (dry basis) 99.0~101.0%

· * The endotoxin-certified grade will be supplied on request.
· ** FCC grade (Lead : Not More Than 5 mg/kg) will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
 

L-Isoleucine


Related News: For example, an active ingredient to relieve pain is included in a painkiller.2-Cyano-6-methylpyridine CAS:1620-75-3 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.4-Bromo-2,6-diphenylpyrimidine INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.1193-79-9 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.

Related Products
Product Name
2-Bromo-4-fluoroanisole View Details
Thioacetic acid View Details
N,6,6-trimethylhept-2-en-4-yn-1-amine View Details
5-Bromo-3-(Trifluoromethyl)-2-Pyridinecarbonitrile manufacturer (1R,2S)-Methyl 1-amino-2-vinylcyclopropanecarboxylate 4-methylbenzenesulfonate manufacturer thymidine manufacturer Cis-1,2,3,6-Tetrahydrophthalic Anhydride manufacturer 3-Bromo-5-(trifluoromethyl)pyridine manufacturer